Clinical trial

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06236438

Drugs and interventions used in this trial

7 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Livmoniplimab Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Budigalimab Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pembrolizumab Normalized identity: pembrolizumabView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pemetrexed Normalized identity: pemetrexedView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Cisplatin Normalized identity: cisplatinView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Carboplatin Normalized identity: carboplatinView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2, PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-04-10

PhasePHASE2 / PHASE3

Conditions

Non-Small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Interventions

LivmoniplimabDRUG

BudigalimabDRUG

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

PemetrexedDRUG · verified · RxNorm: pemetrexed

CisplatinDRUG · verified · RxNorm: cisplatin

CarboplatinDRUG · verified · RxNorm: carboplatin

Sponsors & collaborators

AbbVielead sponsor

Mapped research locations

MadridSpain2 BarcelonaSpain2 TaipeiTaiwan2 AnkaraTurkey (Türkiye)2 HoustonTexas, United States1 ChicagoIllinois, United States1 St LouisMissouri, United States1 San AntonioTexas, United States1 CincinnatiOhio, United States1 ValenciaSpain1 La JollaCalifornia, United States1 LexingtonKentucky, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06236438 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.